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Background-—Bleeding risk stratiﬁcation in acute coronary syndrome is of highest clinical interest but current risk scores have
limitations. We sought to develop and validate a new in-hospital bleeding risk score for patients with acute myocardial infarction.
Methods and Results-—From the nationwide SWEDEHEART (Swedish Web-System for Enhancement and Development of
Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies) register, 97,597 patients with acute
myocardial infarction enrolled from 2009 until 2014 were selected. A full model with 23 predictor variables and 8 interaction terms
was ﬁtted using logistic regression. The full model was approximated by a model with 5 predictors and 1 interaction term.
Calibration, discrimination, and clinical utility was evaluated and compared with the ACTION (Acute Coronary Treatment and
Intervention Outcomes Network) and CRUSADE (Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse
Outcomes With Early Implementation of the ACC/AHA Guidelines) scores. Internal and temporal validity was assessed. In-hospital
major bleeding, deﬁned as fatal, intracranial, or requiring surgery or blood transfusion, occurred in 1356 patients (1.4%). The 5
predictors in the approximate model that constituted the SWEDEHEART score were hemoglobin, age, sex, creatinine, and C-
reactive protein. The ACTION and CRUSADE scores were poorly calibrated in the derivation cohort and therefore were recalibrated.
The SWEDEHEART score showed higher discriminative ability than both recalibrated scores, overall (C-index 0.80 versus 0.73/
0.72) and in all predeﬁned subgroups. Decision curve analysis demonstrated consistently positive and higher net beneﬁt for the
SWEDEHEART score compared with both recalibrated scores across all clinically relevant decision thresholds. The original ACTION
and CRUSADE scores showed negative net beneﬁt.
Conclusions-—The 5-item SWEDEHEART score discriminates in-hospital major bleeding in patients with acute myocardial infarction
and has superior model performance compared with the recalibrated ACTION and CRUSADE scores. ( J Am Heart Assoc. 2019;8:
e012157. DOI: 10.1161/JAHA.119.012157.)
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A dvances in the management of acute coronary syndrome(ACS), including the use of invasive strategies, the
implementation of dual antiplatelet therapy and more efﬁcient
antithrombotic treatment, has been associated with a decline
in mortality across a number of countries.1–3 Yet, such
improvements come at the price of an increased risk of
bleeding and associated mortality and morbidity.4–8 Given
that harm associated with bleeding may attenuate the net
beneﬁt of antithrombotic therapies,9,10 there is international
interest in initiatives to reduce bleeding complications in the
context of ACS.
Guidelines from North America and Europe emphasize that
bleeding risk as well as ischemic risk should be assessed.11,12
While the GRACE (Global Registry of Acute Coronary Events)
risk score13 is advocated for estimating future ischemic
risk11,12 and has been validated in numerous studies to show
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good or excellent model performance,14 there is a paucity of
in-hospital bleeding risk models that demonstrate good model
performance. Of the ACTION (Acute Coronary Treatment and
Intervention Outcomes Network),15 ACUITY (Acute Catheter-
ization and Urgent Intervention Triage Strategy),16 and
CRUSADE (Can Rapid Risk Stratiﬁcation of Unstable Angina
Patients Suppress Adverse Outcomes With Early Implemen-
tation of the ACC/AHA Guidelines)17 bleeding risk scores, the
latter score is the most established but is limited by weak
discriminative ability especially among patients with ACS
managed noninvasively, the elderly, patients prescribed oral
anticoagulants (OACs), and patients with renal failure
(glomerular ﬁltration rate <60 mL/min).18–21 In the European
Society of Cardiology (ESC) guidelines,12 the CRUSADE score
has a class IIb recommendation restricted to patients
receiving coronary angiography.
The aim of the present study was to develop and validate a
new risk score for in-hospital major bleeding in a population
including the aforementioned vulnerable subgroups. The
SWEDEHEART (Swedish Web-System for Enhancement and
Development of Evidence-Based Care in Heart Disease
Evaluated According to Recommended Therapies) registry is
an established national register highly representative of the
Swedish ACS population, thereby enabling generalizable
patient-speciﬁc research into the care and outcomes of
patients hospitalized with ACS.
Methods
The data and study materials will not be made available to
other researchers for purposes of reproducing the results or
replicating the procedure. However, a detailed description of
the analytical method and the full equation is provided in Data
S1.
The SWEDEHEART registry has been previously
described.22 Brieﬂy, it is a national registry of patients
hospitalized for suspected ACS or undergoing coronary or
valve intervention. All Swedish hospitals (n=72) participate,
covering 90% of patients with acute myocardial infarction
(MI) treated in hospitals in Sweden. The registry is regularly
monitored with 95% to 96% agreement with regard to key
variables between the registry and electronic health records.
In order to use a contemporary and reasonably large
population, we selected all consecutive patients with acute
MI, deﬁned as discharge International Classiﬁcation of
Diseases, 10th Revision (ICD-10) code I21 enrolled in the
SWEDEHEART registry from January 1, 2009, until October 10,
2014 (n=109 714). After excluding 11 937 readmissions,
multiple imputation was performed on the remaining 97 777
index hospitalizations. Subsequently, 180 (0.2%) patients with
missing outcome data were excluded, resulting in a derivation
cohort of 97 597 patients.
All Swedish residents are given a unique and permanent
personal identiﬁcation number that allows cross-matching
between several national registries. This made it possible to
enrich baseline data by merging SWEDEHEART with the
National Patient Registry, which contains information on
discharge ICD codes from all admissions to Swedish hospitals
since 1987.
All patients are informed about their participation in the
registry and that they are allowed to opt out. Written consent
is not required according to Swedish law. Patients were
anonymized by a unique study identiﬁcation number before
the data analysis. The study protocol was approved by the
regional ethics committee in Stockholm. The National Board
of Health and Welfare approved the merging of registries.
The outcome was in-hospital non–coronary artery bypass
graft major bleeding deﬁned as fatal, intracranial, or bleeding
requiring blood transfusion or surgery (including endoscopic
and vascular intervention) according to the SWEDEHEART
registry. Other bleeding events were not recorded in the
registry. For patients who underwent coronary artery bypass
Clinical Perspective
What Is New?
• From a population of patients with acute myocardial
infarction representative of a whole nation, we developed
a simple 5-item (age, sex, hemoglobin, creatinine, and C-
reactive protein) in-hospital bleeding risk score that showed
better model performance overall and in all important
subgroups where the current guideline-recommended
CRUSADE (Can Rapid Risk Stratiﬁcation of Unstable Angina
Patients Suppress Adverse Outcomes With Early Implemen-
tation of the ACC/AHA Guidelines) score and the ACTION
(Acute Coronary Treatment and Intervention Outcomes
Network) score underachieved.
• Our results also demonstrate that calibration as well as
discrimination is of upmost importance when evaluating
model performance.
What Are the Clinical Implications?
• Bleeding risk assessment by the CRUSADE score is listed as
one of the main quality indicators for acute myocardial
infarction care by the European Society of Cardiology (ESC).
However, the ESC guidelines give use of the CRUSADE
score a cautious class IIb recommendation restricted to
patients undergoing coronary angiography and the American
guidelines do not recommend the use of a speciﬁc risk
score for bleeding.
• Our score seems valuable in the early assessment of
patients and furthermore our ﬁndings stress the need for
validation and, if necessary, recalibration before applying a
risk score to a new population.
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graft surgery during the same hospital stay, bleeding was only
registered if it occurred before surgery.
All laboratory data (including hemoglobin, C-reactive protein
[CRP], and creatinine) were recorded on admission to the
hospital. Renal function was measured as creatinine and the
glomerular ﬁltration rate was estimated using the Chronic
Kidney Disease Epidemiology Collaboration equation.23 Heart
failure at presentation was deﬁned as any pulmonary rales or
pulmonary edema. Previous bleeding was deﬁned as any
hospitalization with an ICD-10 bleeding diagnosis (listed in
Table S1) before the date of index acute MI.
Statistical Analysis
A detailed description of the statistical methods including an
expanded list of references is presented in Data S1. Before
any model ﬁtting, 23 predictor variables (age, sex, body
weight, hypertension, diabetes mellitus, previous MI, previous
percutaneous coronary artery intervention, previous coronary
artery bypass graft surgery, previous stroke, peripheral artery
disease, chronic heart failure, previous bleeding, single aspirin
therapy, dual antiplatelet therapy, OAC therapy, cardiopul-
monary resuscitation before hospital, atrial ﬁbrillation at
Figure 1. Calibration plots for the ACTION (Acute Coronary Treatment and Intervention Outcomes Network), recalibrated ACTION, CRUSADE
(Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines),
recalibrated CRUSADE, and SWEDEHEART (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease
Evaluated According to Recommended Therapies) scores. Deviations from perfect calibration (Ideal) represent bias in the predicted probabilities.
For the ACTION and CRUSADE scores, the ﬁgure illustrates the observed proportion of bleeding in the derivation cohort (with 95% CIs) vs the
proportion of bleeding in the previously published original derivation cohorts (Apparent). For the recalibrated ACTION and CRUSADE scores and
the SWEDEHEART score, the ﬁgure illustrates the observed proportion of bleeding in the derivation cohort (with 95% CIs) vs the predicted
probability of bleeding (Apparent) and its optimism-corrected estimate (Optimism-corrected). The apparent and optimism-corrected calibration
curves are almost indistinguishable, indicating no overﬁtting.
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hospitalization, cardiogenic shock, heart failure at hospital-
ization, ST-segment–elevation MI, serum creatinine, CRP, and
hemoglobin) were selected based on clinical relevance. In the
derivation cohort, the percentage of missing values across
the predictors and the bleeding outcome varied between 0
and 12% (Table S2). In total, 25% of the records were
incomplete in the derivation cohort. Assuming a missing-at-
random mechanism, the incomplete variables across the
index population were imputed under fully conditional spec-
iﬁcation using a random forest-based algorithm,24,25 resulting
in 25 imputed sets. Convergence was reached after 30
iterations. Before any model ﬁtting, all patients with missing
outcome data were removed as recommended by Von
Hippel.26 Models were then ﬁtted to the imputed data sets
and the corresponding estimates were combined into one
overall estimate.27
The full model including all predictors and 8 prespeciﬁed
interactions (age and sex, age and diabetes mellitus, age and
serum creatinine, age and hemoglobin, sex and body weight,
sex and diabetes mellitus, sex and serum creatinine, and sex
and hemoglobin) was ﬁtted to the outcome variable using
logistic regression. The continuous predictors (age, body
weight, serum creatinine, hemoglobin, and CRP) were
truncated at the ﬁrst and 99th percentiles to limit the
inﬂuence of extreme values. In addition, skewed predictors
(body weight and serum creatinine) were log-transformed. All
continuous predictors were modeled using restricted cubic
splines to allow for nonlinear relationships. Since the full
model was too complex for routine use, a simpliﬁed approx-
imate model was developed using the stepdown method.28
The approximate model was termed the SWEDEHEART score
and presented in the form of a nomogram and an equation.
Risk classes were created according to <0.5%, 0.5% to 1%, 1%
to 2%, 2% to 4%, and >4% predicted risk of in-hospital major
bleeding.
Given that the ACTION and CRUSADE scores were poorly
calibrated in the derivation cohort (Figure 1), recalibrated
scores were obtained by ﬁtting a logistic regression model
using the ACTION and CRUSADE score, respectively, as the
only predictor and the binary bleeding indicator as the
outcome.29
The C-index was used to assess discrimination. Calibra-
tion was assessed graphically using smooth nonparametric
regression and the corresponding CIs were obtained using
2000 bootstrap samples.30,31 Discrimination and calibration
were evaluated in the full derivation cohort and in prede-
ﬁned subgroups. The recalibrated ACTION and CRUSADE
scores and the SWEDEHEART score were internally validated
using 200 bootstrap samples. Temporal validity of the
SWEDEHEART score was assessed using internal–external
cross-validation32 where each admission year was omitted in
turn. The optimism (bias caused by overﬁtting) was
Table 1. Baseline Characteristics
No Major Bleed Major Bleed
(n=96 241) (n=1356)
Demography
Age, y 72 (63–81) 77 (69–83)
Weight, kg 78 (69–90) 74 (64–85)
Women 33 779 (35.1) 621 (45.8)
Medical history
Hypertension 54 923 (57.1) 916 (67.6)
Diabetes mellitus 23 172 (24.1) 411 (30.3)
Previous MI 23 268 (24.2) 398 (29.4)
Previous PCI 13 295 (13.8) 200 (14.7)
Previous CABG 8286 (8.6) 145 (10.7)
Previous PAD 5641 (5.9) 157 (11.6)
Previous stroke 11 498 (11.9) 259 (19.1)
Chronic heart failure 13 647 (14.2) 337 (24.9)
Previous bleeding 5918 (6.1) 170 (12.5)
COPD 6986 (7.3) 142 (10.5)
Previous cancer 3176 (3.3) 91 (6.7)
Medication on admission
b-Blocker 35 771 (37.2) 633 (46.7)
RAS blockade 59 934 (62.3) 739 (54.5)
Calcium antagonist 18 368 (19.1) 324 (23.9)
Digoxin 2052 (2.1) 48 (3.5)
Statins 28 056 (29.2) 481 (35.5)
Diuretics 23 301 (24.2) 500 (36.9)
Aspirin 35 389 (36.8) 602 (44.4)
DAPT 3933 (4.1) 86 (6.3)
OAC 5417 (5.6) 108 (8.0)
Presentation
CPR before hospital 1708 (1.8) 37 (2.7)
Atrial fibrillation 10 262 (10.7) 213 (15.7)
Heart rate, bpm 79 (66–93) 86 (70–100)
Systolic blood pressure, mm Hg 147 (130–167) 140 (120–160)
Symptoms or signs of HF 11 312 (11.8) 288 (21.2)
Shock 1214 (1.3) 36 (2.7)
ST-elevation 31 991 (33.2) 457 (33.7)
Laboratory data on admission
Hemoglobin, g/L 139 (127–149) 116 (101–131)
Anemia WHO definition 19 729 (20.5) 818 (60.3)
Creatinine, mmol/L 84 (70–103) 99 (77–137)
GFR by CKD-EPI, mL/min 74 (55–89) 56 (37–76)
CRP 5 (3–15) 17 (5–66)
Values are expressed as median (interquartile range) or number (percentage). bpm
indicates beats per minute; CABG, coronary artery bypass graft; CKD-EPI, Chronic Kidney
Disease Epidemiology Collaboration; COPD, chronic obstructive pulmonary disease; CPR,
cardiopulmonary resuscitation; CRP, C-reactive protein; DAPT, dual antiplatelet therapy;
GFR, glomerular ﬁltration rate; HF, heart failure; MI, myocardial infarction; OAC, oral
anticoagulant; PAD, peripheral artery disease; PCI, percutaneous coronary intervention;
RAS, renin-angiotensin system; WHO, World Health Organization.
DOI: 10.1161/JAHA.119.012157 Journal of the American Heart Association 4
The Novel SWEDEHEART Bleeding Risk Score Simonsson et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on March 21, 2019
estimated and optimism-corrected performance estimates
were obtained.
The clinical utility of the ACTION, CRUSADE, and SWEDE-
HEART scores was evaluated using decision curve analysis.33
Using a score to classify patients into low- and high-risk
bleeders requires a decision threshold, classifying all patients
with a predicted bleeding probability above the threshold as
high-risk bleeders. Since the score is not perfect, the resulting
decision will either be incorrect (a false-positive bleed) or
correct (a true-positive bleed). The net beneﬁt of using a score
at a given threshold is deﬁned as the difference between the
proportion of true positives and the proportion of false
positives weighted by the odds of the threshold, where the
weight corresponds to the cost-beneﬁt ratio associated with
incorrect and correct decisions. For a given threshold, a score
is considered clinically useful if it has a positive net beneﬁt
and harmful if the net beneﬁt is negative. For each score, the
decision curve illustrates the net beneﬁt corresponding to the
decision thresholds. The score with the higher net beneﬁt
across the range of clinically relevant decision thresholds is
preferred.
Methods and results are presented in line with the
transparent reporting of a multivariable prediction model for
individual prognosis or diagnosis (TRIPOD) statement.34 All
statistical analyses were performed with R (version 3.4.3, The
R Foundation for statistical computing) using the add-on
packages mice (version 2.44) and rms (version 5.1–1).
Results
Baseline Characteristics and in-Hospital Course
Baseline characteristics on admission of patients with and
without major in-hospital bleeding are listed in Table 1. The
median time to discharge was 4 days (interquartile range, 3–6
days). Major bleeding occurred in 1356 patients (1.4%), and,
of these, 50 (0.1%) were fatal, 114 (0.1%) were cerebral, and
1192 (1.2%) required surgery or red blood cell transfusion.
Patients with a bleeding event were older (median 77 years
versus 72 years), more often female (46% versus 35%) and
had an overall higher preexisting burden of comorbidity and
more extensive medication, including single aspirin therapy
(36.8% versus 44.4%), dual antiplatelet therapy (4.1% versus
6.3%), or OAC therapy (5.6% versus 8.0%).
Patients with a major bleeding event less frequently
received an invasive coronary strategy (angiography 56.9%
versus 77.2% and percutaneous coronary intervention 43.9%
versus 60.3%). In addition, having a major bleeding event
was associated with a 3-fold incidence of new-onset atrial
ﬁbrillation, cardiac arrest, and death, and a 4- and 5-fold
Table 2. In-Hospital Course
Variable
Major Bleeding
Total (N=97 597)No (n=96 241) Yes (n=1356)
Treatment
Angiography 74 284 (77.2) [0] 772 (56.9) [0] 75 056 (76.9) [0]
PCI 58 002 (60.3) [0] 607 (44.8) [0] 58 609 (60.1) [0]
Fondaparinux 48 749 (50.7) [159] 458 (33.8) [4] 49 207 (50.4) [163]
Heparin 5495 (5.7) [159] 77 (5.7) [4] 5572 (5.7) [163]
LMWH 10 057 (10.4) [159] 307 (22.6) [4] 10 364 (10.6) [163]
Diuretics 18 444 (19.2) [92] 646 (47.6) [2] 19 090 (19.6) [94]
Inotropic drugs 2934 (3.0) [88] 193 (14.2) [4] 3127 (3.2) [92]
Thrombolysis 1599 (1.7) [0] 35 (2.6) [0] 1634 (1.7) [0]
Evaluation (echocardiography)
LVEF <50% 30 220 (31.4) [23 891] 595 (43.9) [351] 30 815 (31.6) [24 332]
Complications
New-onset atrial fibrillation 3936 (4.1) [1603] 158 (11.7) [6] 4094 (4.2) [1609]
Reinfarction 662 (0.7) [131] 37 (2.7) [1] 699 (0.7) [132]
Shock in hospital 1960 (2.0) [1502] 137 (10.1) [2] 2097 (2.1) [1504]
CPR 3038 (3.2) [15] 138 (10.2) [0] 3176 (3.3) [15]
Death 4595 (4.8) [12] 198 (14.6) [0] 4793 (4.9) [12]
Values are expressed as number (percentage) [missing]. CPR indicates cardiopulmonary resuscitation; LMWH, low-molecular-weight heparin; LVEF, left ventricular ejection fraction; PCI,
percutaneous coronary intervention.
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incidence of reinfarction and in-hospital shock, respectively
(Table 2).
Model Performance and Validation
The full model including all predictors and interactions
(Figure S1) had a C-index of 0.81 (95% CI, 0.80–0.82). The
internal validation indicated only modest overﬁtting with an
optimism-corrected C-index and a calibration slope of 0.80
and 1.04, respectively. The approximate model including only
the 5 most important predictors (hemoglobin, age, sex,
creatinine, and CRP) and 1 interaction term (hemoglobin and
sex) represented 92.7% of the full model and was termed the
SWEDEHEART score, presented as a nomogram (Figure 2) and
equation (Figure S2). The SWEDEHEART score had a C-index
of 0.80 (95% CI, 0.79–0.81) with an optimism-corrected C-
index and a calibration slope of 0.80 and 0.99 respectively,
indicating negligible overﬁtting. The internal-external temporal
validation indicated temporal stability with an optimism
corrected C-index of 0,80. (C in C-index in cursive). The
ACTION and CRUSADE scores had a C-index of 0.73 (95% CI,
0.72–0.74) and 0.72 (95% CI, 0.71–0.74), respectively
(Table 3), which is in agreement with the results presented
in the original publications.15,17
The SWEDEHEART score achieved a consistently higher C-
index than the ACTION and CRUSADE scores in the
subgroups of women, elderly (>75 years), patients managed
noninvasively, patients taking OACs, those with ST-segment–
elevation MI/non–ST-segment–elevation MI, and those with
chronic kidney disease <60 mL/min (Table 3). In the sub-
group of patients managed noninvasively, which consti-
tuted 25% of the study population, the CRUSADE score was
only weakly discriminative, with a C-index of 0.59 (95% CI,
0.57–0.62).
The ACTION and CRUSADE scores were poorly calibrated in
the derivation cohort (Figure 1), and when recalibrated had an
Figure 2. Nomogram for the SWEDEHEART (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease
Evaluated According to Recommended Therapies) score. To use the nomogram for an individual patient, the points for each predictor are read at the
vertical line from the predictor value to the Points line (top). The total points are calculated and a vertical line from this value on the Total Points line to
the Bleeding Risk line (bottom) provides the estimated probability of in-hospitalmajor bleeding risk. Total points<6 or>14 corresponds to a bleeding
risk <0.5% or >10%, respectively. Example 1: men with hemoglobin=135, age=85 years, C-reactive protein (CRP)=10, and creatinine=130. The
points corresponding to each predictor are roughly 1.8, 2.2, 0.7, and 2.3. The total points are 7, corresponding to an in-hospitalmajor bleeding risk of
0.7%. Example 2: women with hemoglobin=135, age=85 years, CRP=10, and creatinine=130. The points corresponding to each predictor are
roughly 3.3, 2.2, 0.7, and 2.3. The total points are 8.5, corresponding to an in-hospital major bleeding risk of 1.2%.
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optimism-corrected C-index of 0.73 and 0.72, respectively, and
a calibration slope of 1.0 in both cases, indicating no overﬁtting.
The recalibrated ACTION and CRUSADE scores and the
SWEDEHEART score showed comparable calibration (Figure 1)
for bleeding probabilities between 1% and 4%, whereas the
SWEDEHEART score demonstrated superior calibration for
bleeding probabilities <1% and >4%. Calibration plots compar-
ing the recalibrated ACTION and CRUSADE scores and the
SWEDEHEART score in all subgroups are shown in Figure S3.
The observed bleeding risks within the ACTION, CRUSADE, and
SWEDEHEART risk classes are illustrated in Figures 3 and 4.
The SWEDEHEART score demonstrated improved risk stratiﬁ-
cation within the ACTION and CRUSADE risk classes (Fig-
ures 3A and 4A), whereas the ACTION and CRUSADE scores
did not improve the risk stratiﬁcation within the SWEDEHEART
risk classes (Figures 3B and 4B).
Clinical utility was evaluated using decision curve analy-
sis.33 Across the range of clinically relevant decision thresh-
olds, the SWEDEHEART score had consistent positive and
larger net beneﬁt in comparison with the recalibrated ACTION
and CRUSADE scores (Figure 5). For example, at a threshold
of 2% in-hospital major bleeding risk, the SWEDEHEART score
will identify 2.0 and 2.3 additional in-hospital major bleeds
compared with the recalibrated ACTION and CRUSADE
scores, respectively, in a population with 13.9 in-hospital
major bleeds per 1000 individuals, without increasing the
number of false-positives. Because of their poor calibration,
the original ACTION and CRUSADE scores showed negative
Table 3. C-index for the ACTION, CRUSADE, and SWEDEHEART Scores
No. Bleeds
C-Index
ACTION CRUSADE SWEDEHEART
Overall 97 597 1356 0.73 (0.72–0.74) 0.72 (0.71–0.74) 0.80 (0.79–0.81) [0.80]
Sex
Women 34 400 621 0.68 (0.66–0.70) 0.66 (0.64–0.68) 0.74 (0.72–0.76) [0.74]
Men 63 197 735 0.76 (0.74–0.78) 0.76 (0.74–0.77) 0.83 (0.81–0.84) [0.82]
Missing 0
Age, y
<75 56 002 572 0.77 (0.75–0.79) 0.76 (0.74–0.78) 0.81 (0.80–0.83) [0.81]
≥75 41 594 784 0.67 (0.65–0.69) 0.65 (0.64–0.67) 0.76 (0.75–0.78) [0.76]
Missing 1
Anticoagulation
No 91 204 1228 0.73 (0.72–0.75) 0.72 (0.71–0.74) 0.80 (0.79–0.81) [0.80]
Yes 5525 108 0.71 (0.67–0.76) 0.70 (0.65–0.74) 0.77 (0.73–0.82) [0.77]
Missing 868
Angiography
No 22 541 584 0.63 (0.61–0.65) 0.59 (0.57–0.62) 0.76 (0.74–0.79) [0.76]
Yes 75 056 772 0.75 (0.73–0.77) 0.74 (0.73–0.76) 0.79 (0.78–0.81) [0.79]
Missing 0
STEMI
No 64 730 896 0.74 (0.73–0.76) 0.72 (0.71–0.74) 0.82 (0.80–0.83) [0.81]
Yes 31 304 447 0.74 (0.72–0.76) 0.73 (0.71–0.75) 0.77 (0.75–0.79) [0.77]
Missing 1563
GFR
<60 28 236 715 0.66 (0.65–0.68) 0.65 (0.63–0.67) 0.75 (0.73–0.77) [0.75]
≥60 63 999 578 0.73 (0.71–0.75) 0.71 (0.69–0.73) 0.79 (0.77–0.81) [0.78]
Missing 5362
C-index (95% CI) (if possible C in C-index in cursive). ACTION indicates Acute Coronary Treatment and Intervention Outcomes Network; CRUSADE, Can Rapid Risk Stratiﬁcation of Unstable
Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines; GFR, glomerular ﬁltration rate; STEMI, ST-segment–elevation myocardial infarction;
SWEDEHEART, Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies.
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net beneﬁt (Tables S3 and S4). In the same setting as above,
the SWEDEHEART score will identify 11.3 additional in-
hospital major bleeds compared with the original ACTION and
CRUSADE scores.
If CRP was not available, we made an alternate SWEDE-
HEART score without CRP. This alternate score represented
88.2% of the full model and had a C-index of 0.79 (95% CI,
0.77–0.80) and an optimism-corrected C-index and calibra-
tion slope of 0.78 and 1.0, respectively. A more detailed
description including nomogram, calibration curve, and equa-
tion for the SWEDEHEART score without CRP is shown in
Table S5 and Figures S4 through S6.
Discussion
In this study we developed and validated a new risk score
for in-hospital major bleeding in nearly 100 000 patients
with acute MI. Our new score, based on the 5 base-
line variables (hemoglobin, age, sex, creatinine, and CRP)
showed good discrimination and calibration across different
subgroups. The ACTION score and the currently recom-
mended CRUSADE score was, even after recalibration,
inferior to the SWEDEHEART score and, as previously
described, especially unfavorable in patients not undergoing
coronary angiography.19
Need for Validation and Recalibration of Scores
The ACTION and CRUSADE scores have already been
externally validated in several populations. However, both
scores were associated with negative net beneﬁt in the
derivation cohort, indicating that their use was harmful. This
ﬁnding is of additional clinical importance since it stresses the
need for validation and, if needed, recalibration before
applying a risk score to a new population.
Figure 3. Observed bleeding risk within the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) and
SWEDEHEART (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According
to Recommended Therapies) risk classes. Observed bleeding risk and corresponding 95% CIs are illustrated within the ACTION and
SWEDEHEART risk classes. In (A) the observed bleeding risk within the ACTION risk classes is shown for each SWEDEHEART risk class,
demonstrating high variability of the observed bleeding risk and low agreement between the observed bleeding risk and the ACTION risk
classes. In (B) the observed bleeding risk within the SWEDEHEART risk classes is shown for each ACTION risk class, showing low
variability of the observed bleeding risk and high agreement between observed bleeding risk and the SWEDEHEART risk classes.
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Comparison With Other Scores
What makes our score unique is that it was derived from a
cohort including almost all patients hospitalized with acute MI
in Sweden over a study period of almost 6 years. Of the entire
index population of 97 777 patients, only 180 (0.2%) patients
with missing outcome data were excluded. An internal–
external cross-validation was used to assess the temporal
validity of the score within the geographical area. The ACTION
and CRUSADE registers comprised selected patients on a
national level since they only covered a small proportion of US
hospitals. There is also lack of data regarding the proportion
of patients with ACS who were included in the registries at
participating hospitals. CRUSADE only included non–ST-
segment–elevation MI and excluded patients receiving
OACs. Both the ACTION and CRUSADE derivation cohorts
excluded patients with missing data on certain baseline
variables as well as patients who died within 24 and 48 hours,
respectively.15,17 The ACUITY score was derived from 2
randomized controlled trials and thus included a strongly
selected population.16
Overall Low Incidence of Bleeding
The incidence of major bleeding in our derivation cohort was
low (1.4%) compared with ACTION (10.8%), ACUITY (7.3%),
and CRUSADE (9.4%). There are many plausible explanations
for this ﬁnding. Comparison of bleeding incidence is depen-
dent not only on the deﬁnition but also the characteristics
and treatment patterns of the population. Our bleeding
deﬁnition did only include non–coronary artery bypass graft–
related bleeds that were fatal, were intracranial, or that led to
blood transfusion or intervention during a short observation
period. Bleedings with only a large drop in hemoglobin were
not counted. In the CRUSADE population, femoral access was
dominating and glycoprotein IIb/IIIa blockers were used more
Figure 4. Observed bleeding risk within the CRUSADE (Can Rapid Risk Stratiﬁcation of Unstable Angina Patients Suppress Adverse
Outcomes With Early Implementation of the ACC/AHA Guidelines) and SWEDEHEART (Swedish Web-System for Enhancement and
Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies) risk classes. Observed
bleeding risk and corresponding 95% CIs are illustrated within the CRUSADE and SWEDEHEART risk classes. In (A) the observed
bleeding risk within the CRUSADE risk classes is shown for each SWEDEHEART risk class, demonstrating high variability of the
observed bleeding risk and low agreement between the observed bleeding risk and the CRUSADE risk classes. In (B) the observed
bleeding risk within the SWEDEHEART risk classes is shown for each CRUSADE risk class, showing low variability of the observed
bleeding risk and high agreement between observed bleeding risk and the SWEDEHEART risk classes.
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frequently. Since then, several bleeding avoidance strategies
have been implemented and most of the patients in our
derivation cohort were treated through radial access, few
received glycoprotein IIb/IIIa blockers, and new drugs
(fondaparinux and bivalirudin) with a lower risk of bleeding
were used. Finally, but not least important, when using a
bleeding deﬁnition including transfusion, the bleeding inci-
dence may also reﬂect the transfusion strategy in the study
population. Our bleeding deﬁnition differed from the CRU-
SADE deﬁnition, which included hemoglobin drops and
retroperitoneal bleeds. The transfused bleeds constituted
over 6% in the CRUSADE population compared with only 1.2%
in the SWEDEHEART population, which may suggest either
more severe bleeds that led to transfusion and/or a more
liberal transfusion strategy in the CRUSADE population.
Geographical variation in transfusion strategy with a signif-
icantly higher incidence in US compared with non-US
countries has been described by Rao et al,35 even though
the rate of transfusion in patients undergoing percutaneous
coronary intervention in the United States has declined over
the past years.36
Theremaybeunderreportingofbleedingeventsbut the register
is regularly monitored with 95% to 96% variable agreement.
Anemia as a Marker of Increased Risk
The strong association between anemia and bleeding is
to some extent a result of our bleeding deﬁnition as well as
the fact that preexisting anemia by itself may exacerbate
the consequences of bleeding. Bleeding in patients with
normal or high hemoglobin levels at baseline will more
seldom lead to red blood cell transfusion, whereas bleeding
in patients with anemia at baseline will more often be
followed by an intervention. Nonfatal bleeding with large
drop in hemoglobin without red blood cell transfusion or
surgery was not registered as a bleeding event in the
registry. Finally, preexisting anemia may reﬂect prior or
ongoing occult bleeding, which will become manifest when
Figure 5. Decision curve analysis. For each decision threshold, the net beneﬁt of the recalibrated ACTION
(Acute Coronary Treatment and Intervention Outcomes Network) and CRUSADE (Can Rapid Risk
Stratiﬁcation of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the
ACC/AHA Guidelines) scores and the SWEDEHEART (Swedish Web-System for Enhancement and
Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies)
score is shown. In addition, the net beneﬁt assuming that all patients have a bleeding risk higher than the
threshold (all risk high) as well as the net beneﬁt assuming that all patients have a bleeding risk lower than
the threshold (all risk low) are shown. For a given threshold, the difference in net beneﬁt between two
scores is the additional number of bleeds identiﬁed (per 1000) without increasing the number of false
positive classiﬁcations. Across the range of decision thresholds, the SWEDEHEART score was consistently
positive and had larger net beneﬁt than the recalibrated ACTION and CRUSADE scores.
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treated with antithrombotic treatment in the course of an
ACS.
Inﬂammation as a Marker of Increased Risk
The variable CRP may be questioned because it is nonspeciﬁc,
but markers of inﬂammation are certainly of interest for
prediction of bleeding events. A small study in the elderly has
shown that the addition of CRP and previous bleeding
improved the discriminative ability of the CRUSADE score.37
In the ACUITY score and the PRECISE-DAPT38 inﬂammatory
status is reﬂected by white blood cell count. Recent work
from the PLATO (Platelet Inhibition and Patient Outcome) and
ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects
With Atrial Fibrillation) studies showed that growth differen-
tiation factor 15, a marker of inﬂammation and cell ageing,
was strongly associated with bleeding.39–41 Elevated CRP has
also been shown to be associated with both upper and lower
GI bleeding42,43 as well as malignancy.44 As expected, the
alternate SWEDEHEART score without CRP explained less
(88.2%) of the full model compared with the score with CRP
(92.6%), but the alternate score without CRP was still useful,
with only slightly lower discriminative ability.
Need for Risk Scores
Assessment of patients with ACS and an indication for
treatment in clinical practice are often not as clear-cut as in
clinical trials and clinical guidelines. When deciding on
intensity of antithrombotic treatment, physicians often have
to weigh the ischemic risk against the bleeding risk. Objective
assessment of ischemic risk by the GRACE score has been
shown to be superior to physician-estimated ischemic risk.45
With an accutare bleeding risk score the same should
probabably hold true for assessment of bleeding risk.
Bleeding risk assessment by the CRUSADE score is listed
as one of the main quality indicators for in-hospital risk
assessment in acute MI by the ESC Acute Cardiovascular
Care Association Quality of Care Working Group.46 Our new
risk model is complex but still easy to use provided a
calculator on a computer or smartphone or delivered by
decision support. A simple head-calculation score with
dichotomized variables may be even more easy to use, but
may result in less precise risk estimates and decisions about
treatment. Still, we will need future trials that can more
exactly deﬁne how our score should inﬂuence clinical decision
making.
Strengths and Limitations
While there are strengths to our methodological approach
including size, completeness, and the state-of-art derivation
and validation, we acknowledge some study limitations.
Although our results should be considered as highly valid in
Sweden (with similar patients with ACS and coronary care as
the rest of the Western world), lack of external validation in
other geographically deﬁned populations in which the score
will be used is still a limitation of the study. But this holds true
for all scores. Our bleeding deﬁnition was limited by the
variables available in our register and therefore we could not
use the CRUSADE or any other standardized bleeding
deﬁnition. Nor did we have information on type of bleeding
and, thus, outcome associated with different subtypes of
bleeding could not be evaluated.
Using a different bleeding deﬁnition and also the temporal
aspect with implementation of bleeding avoidance strategies
since the CRUSADE era may have limited the performance of
the CRUSADE score in our study population. Furthermore,
hematocrit level was unavailable in the derivation cohort and
replaced by hemoglobin converted to hematocrit for calcula-
tion of the CRUSADE score, which may be less exact. We also
lacked data regarding dosing of antithrombotic treatment,
which may have inﬂuenced the explanatory value of the full
model.
Conclusions
The SWEDEHEART score, based on the variables hemoglobin,
creatinine, age, sex, and CRP, offers better prediction of major
in-hospital bleeding in acute MI than the ACTION score and
the currently recommended CRUSADE score.
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Supplemental Statistical Methods (detailed) 
Variable selection 
Prior to any model fitting, the predictor variables (age, sex, body weight, hypertension, 
diabetes, previous myocardial infarction, previous percutaneous coronary artery intervention, 
previous coronary artery bypass grafting surgery, previous stroke, peripheral artery disease, 
chronic heart failure, previous bleeding, acetylsalicylic acid therapy, dual antiplatelet therapy, 
oral anticoagulant therapy, cardiopulmonary resuscitation before hospital, atrial fibrillation at 
hospitalization, cardiogenic shock, heart failure at hospitalization, ST elevation myocardial 
infarction, serum creatinine, C-reactive protein (CRP) and hemoglobin) were selected based 
on clinical relevance. 
Missing values 
In the derivation cohort, the percentage of missing values across the predictors and the binary 
bleeding outcome varied between 0 and 12%. In total, 25% of the records were incomplete in 
the derivation cohort. To account for the incomplete data, multiple imputation was used. 
Following current recommendations, the number of imputed data sets should be (at least) 
equal to the percentage of missing values and, hence, 25 imputed datasets were created [1]. 
Assuming a missing-at-random mechanism, the incomplete variables across the index 
population were imputed under fully conditional specification using a random forest-based 
MICE algorithm [2, 3]. All available data was used in the imputation, i.e., subjects with 
missing outcomes were included. The imputation model for the outcome included all the 
predictors, whereas the imputation model for each incomplete predictor included all other 
predictors as well as the outcome. Convergence was reached after 30 iterations, i.e., all 
imputation streams intermingled freely, the between-stream variability was not larger than the 
within-stream variability and all estimates were free of trend. Prior to any model fitting, all 
subjects with missing outcome data were removed as recommended by von Hippel [4]. 
Models were then fitted to the imputed data sets and the corresponding estimates were 
combined into one overall estimate. The associated variance estimates were properly adjusted 
to account for the within- and between-imputation variability [5, 6]. 
Development of the SWEDEHEART score 
The full model including all preselected predictors and prespecified interactions (age and sex, 
age and diabetes, age and serum creatinine, age and hemoglobin, sex and body weight, sex 
and diabetes, sex and serum creatinine, and sex and hemoglobin) was fitted to the outcome 
variable using logistic regression. The continuous predictors (age, body weight, serum 
creatinine, hemoglobin and CRP) were truncated at (roughly) the 1st and 99th percentiles to 
limit the influence of extreme values [7]. In addition, skewed predictors (body weight and 
serum creatinine) were log-transformed. All continuous predictors were modelled using 
restricted cubic splines to allow for nonlinear relationships. The number of knots assigned to 
the spline terms was based on the strength of the association between the outcome and each 
predictor. The strength of the association was assessed by a generalized Spearman rank 
correlation, taking potential nonmonotonic relationships into account. The two predictors 
showing the strongest associations (hemoglobin and CRP) were assigned five and four knots 
respectively, whereas weaker associations (age, body weight and serum creatinine) were 
assigned three knots. 
Since the full model was too complex for routine use, a simplified approximate model was 
developed using the stepdown method [8]. Stepdown is blinded for the outcome, thereby 
Data S1.
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avoiding overfitting and the bias that results from traditional stepwise variable selection 
methods and has even been shown to result in models that may perform better than the full 
model [9]. The approximate model was developed in two steps: First, a standard (ordinary 
least squares) linear regression model was fitted where the estimated linear predictor from the 
full model, i.e., the predicted log-odds, was used as the outcome and all predictors and 
interactions were entered in exactly the same way as in the full model. This model provides, 
by definition, a perfect fit and therefore has an R2 of 1. Second, a backward elimination 
algorithm was applied, carefully respecting marginality so that a main-effect term was not 
removed if included in an interaction term still present in the model, removing the least 
important terms from the model in a stepwise manner. The degree of accuracy with which the 
approximate model represents the linear predictor of the full model was measured by R2. The 
approximate model was presented in the form of a nomogram and an equation. Risk classes 
were created according to <0.5%, 0.5-1%, 1-2%, 2-4% and >4% predicted risk of in-hospital 
major bleeding. 
An alternate approximated model without CRP was also developed using the same stepdown 
method as described above.  
Calculation of the ACTION and CRUSADE scores 
The ACTION and CRUSADE scores were calculated according to [10] and [11]. The 
CRUSADE score [11] includes baseline hematocrit, which was unavailable in the derivation 
cohort. For this reason, hematocrit was replaced by hemoglobin converted to hematocrit. 
Recalibration of the ACTION and CRUSADE scores 
The ACTION and CRUSADE scores were poorly calibrated in the derivation cohort. 
Recalibrated scores were obtained by fitting logistic regression models using the ACTION 
and CRUSADE score, respectively, as the only predictor and the binary bleeding indicator as 
the outcome [12]. 
Discrimination and calibration 
The C-index was used to assess discrimination. Calibration was assessed graphically using 
smooth nonparametric regression and the corresponding confidence intervals were obtained 
using 2000 bootstrap samples [13, 14]. Discrimination and calibration were evaluated in the 
full derivation cohort and in several predefined subgroups. 
Validation 
The discrimination and calibration of the recalibrated ACTION and CRUSADE scores and 
the SWEDEHEART score were internally validated using 200 bootstrap samples. Within each 
bootstrap sample, each model was refitted and its performance in both the bootstrap sample 
(apparent performance) and the original data (test performance) was computed. Temporal 
validity of the SWEDEHEART score was assessed using internal–external cross-validation 
[15, 16], where each admission year was omitted in turn. For each omitted admission year, the 
model was refitted and its apparent performance and its test performance, using the omitted 
admission year, was computed. The optimism, i.e., the bias due to overfitting, was estimated 
as the mean difference between apparent performance and test performance. Using these 
results, optimism-corrected performance estimates were obtained. 
Clinical utility 
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In addition to discrimination and calibration, the clinical utility of the ACTION, CRUSADE 
and SWEDEHEART scores was evaluated using decision curve analysis [17]. Using a score 
to classify patients into low- and high-risk bleeders requires a decision threshold, classifying 
all patients with a predicted bleeding probability above the threshold as high-risk bleeders. 
Since the score is not perfect, the resulting decision will either be incorrect (a false positive 
bleed) or correct (a true positive bleed). The net benefit of using a score at a given threshold is 
defined as the difference between the proportion of true positives and the proportion of false 
positives weighted by the odds of the threshold, where the weight corresponds to the cost-
benefit ratio associated with incorrect and correct decisions. For example, at the threshold of 
2% bleeding risk all patients with a predicted probability larger than 2% are classified as 
high-risk bleeders. This threshold corresponds to a cost-benefit ratio of 1:49, i.e., the benefits 
of a correct decision is 49 times greater than the harms of an incorrect decision. For a given 
threshold, a score is considered clinically useful if it has a positive net benefit and clinically 
harmful if the net benefit is negative. For each score, the decision curve illustrates the net 
benefit corresponding to the decision thresholds. The score with the higher net benefit across 
the range of clinically relevant decision thresholds is preferred. 
Reporting and software 
The reporting followed the TRIPOD statement [18]. All statistical analyses were performed 
with R (version 3.4.3; The R Foundation for Statistical Computing, Vienna, Austria) using the 
add-on packages mice (version 2.44) and rms (version 5.1-1). 
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Table S1. Previous bleeding ICD-10 diagnoses. 
Anemia following acute significant bleeding: D629 
Iron deficiency anemia following chronic blood loss: D500  
Ocular bleeding: H 35.6, H 431, H450 
Bleeding from the ear: H 92.2  
Cerebral and intracranial bleeding:  I60, I61, I62 
Oesophageal varices with bleeding: I850  
Gastrointestinal bleeding: K226, K250, K252, K254, K256, K260, K262, K264, K266, K270, 
K272, K274, K276, K280, K282, K284, K286, K290, K625, K920, K921, K922 
Urogenital bleeding: N421, N501, N938, N939, N950, R319 
Airway bleeding: R041, R042, R048, R049  
Secondary bleeding or hematoma complicating surgery or medical interventions: T810 
Previous bleeding was defined as hospitalization with any of above listed ICD-10 bleeding 
diagnosis prior to the index event. 
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Table S2. Missing observations. 
Major bleeding 
Variable 
No 
(N = 96241) 
Yes 
(N = 1356) 
Total 
(N = 97597) 
Demography 
Age (years) 1   (0.0%) 0   (0.0%) 1   (0.0%) 
Sex  6040   (6.3%) 92   (6.8%) 6132   (6.3%) 
Body weight (kg) 0   (0.0%) 0   (0.0%) 0   (0.0%) 
Medical history 
Hypertension 0   (0.0%) 0   (0.0%) 0   (0.0%) 
Diabetes 0   (0.0%) 0   (0.0%) 0   (0.0%) 
Previous AMI 0   (0.0%) 0   (0.0%) 0   (0.0%) 
Previous PCI 0   (0.0%) 0   (0.0%) 0   (0.0%) 
Previous CABG 0   (0.0%) 0   (0.0%) 0   (0.0%) 
Previous PAD 0   (0.0%) 0   (0.0%) 0   (0.0%) 
Previous stroke 0   (0.0%) 0   (0.0%) 0   (0.0%) 
Previous CHF 0   (0.0%) 0   (0.0%) 0   (0.0%) 
Previous bleeding 0   (0.0%) 0   (0.0%) 0   (0.0%) 
Medication on arrival 
Aspirin 870   (0.9%) 24   (1.8%) 894   (0.9%) 
Dual antiplatelet therapy 861   (0.9%) 24   (1.8%) 885   (0.9%) 
Oral anticoagulant therapy 848   (0.9%) 20   (1.5%) 868   (0.9%) 
Signs and symptoms at presentation 
CPR before hospital 2190   (2.3%) 46   (3.4%) 2236   (2.3%) 
Atrial fibrillation on arrival 3730   (3.9%) 56   (4.1%) 3786   (3.9%) 
Symptoms or signs of HF 3120   (3.2%) 45   (3.3%) 3165   (3.2%) 
Cardiogenic shock 1738   (1.8%) 17   (1.3%) 1755   (1.8%) 
ST-elevation 1550   (1.6%) 13   (1.0%) 1563   (1.6%) 
Hemoglobin (g/l) 7409   (7.7%) 53   (3.9%) 7462   (7.6%) 
Creatinine (µmol/l) 5298   (5.5%) 63   (4.6%) 5361   (5.5%) 
CRP (mg/l) 11522 (12.0%) 131   (9.7%) 11653 (11.9%) 
Data presented as N (%). 
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Table S3. Net benefit for ACTION and SWEDEHEART. 
Net benefit (per 1000 subjects) Advantage 
Threshold (%) 
Cost-benefit 
ratio All high risk ACTION 
Recalibrated 
ACTION SWEDEHEART 
SWEDEHEART 
vs 
ACTION 
SWEDEHART 
vs 
Recalibrated 
ACTION 
0   0:100 = 0:1 13.9 13.9 13.9 13.9 0.0 0.0 
1   1:99 3.9 3.9 6.4 7.4 3.5 0.9 
2   2:98 = 1:49 –6.2 –6.2 3.1 5.1 11.3 2.0 
3   3:97 –16.6 –16.6 1.1 3.9 20.5 2.8 
4   4:96 = 1:24 –27.2 –20.4 0.4 3.0 23.4 2.6 
5   5:95 = 1:19 –38.0 –28.9 0.0 2.3 31.2 2.3 
6   6:94 = 3:47 –49.0 –37.5 –0.2 1.8 39.3 2.0 
7   7:93 –60.3 –45.8 –0.2 1.5 47.3 1.7 
8   8:92 = 2:23 –71.9 –17.7 –0.2 1.1 18.8 1.3 
9   9:91 –83.6 –20.4 –0.3 0.9 21.4 1.2 
10 10:90 = 1:9 –95.7 –23.5 –0.3 0.7 24.2 1.0 
The net benefit for different thresholds in the derivation cohort with 13.9 bleeds per 1000 subjects is shown. For each decision threshold and its 
associated cost-benefit ratio, the net benefit of the ACTION, recalibrated ACTION and SWEDEHEART scores are shown. In addition, the net 
benefit assuming that all patients have a bleeding risk higher than the threshold is shown (All risk high). The net benefit assuming that all patients 
have a bleeding risk lower than the threshold is, by definition, zero. For example, at the threshold of 2% in a population with 13.9 bleeds (per 
1000 subjects), the net benefit of using the ACTION, recalibrated ACTION and SWEDEHEART scores are –6.2, 3.1 and 5.1 bleeds respectively. 
The ACTION and recalibrated ACTION scores are associated with negative net benefit for thresholds of 2-10% and 6-10%, respectively, 
indicating that their use is clinically harmful. The SWEDEHEART score shows a positive net benefit and is considered clinically useful. 
Compared to the ACTION and recalibrated ACTION scores, the advantage of using the SWEDEHEART score at the 2% threshold is 
identification of 11.3 and 2.0 additional bleedings, respectively, without increasing the number of false positive classifications. The 
SWEDEHEART score shows a higher net benefit across all decision thresholds in the range from 1 to 10%. 
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Table S4. Net benefit for CRUSADE and SWEDEHEART.
Net benefit (per 1000 subjects) Advantage 
Threshold (%) 
Cost-benefit 
Ratio All high risk CRUSADE 
Recalibrated 
CRUSADE SWEDEHEART 
SWEDEHEART 
vs 
CRUSADE 
SWEDEHART 
vs 
Recalibrated 
CRUSADE 
0   0:100 = 0:1 13.9 13.9 13.9 13.9 0.00 0.0 
1   1:99 3.9 3.9 6.3 7.4 3.5 1.1 
2   2:98 = 1:49 –6.2 –6.2 2.8 5.1 11.3 2.3 
3   3:97 –16.6 –16.6 1.2 3.9 20.5 2.8 
4   4:96 = 1:24 –27.2 –23.3 0.4 3.0 26.3 2.6 
5   5:95 = 1:19 –38.0 –24.4 0.1 2.3 26.7 2.2 
6   6:94 = 3:47 –49.0 –23.6 0.0 1.8 25.4 1.8 
7   7:93 –60.3 –21.5 –0.1 1.5 23.0 1.6 
8   8:92 = 2:23 –71.9 –19.8 0.0 1.1 20.9 1.1 
9   9:91 –83.6 –17.1 0.0 0.9 18.0 0.9 
10 10:90 = 1:9 –95.7 –15.7 0.0 0.7 16.4 0.7 
The net benefit for different thresholds in the derivation cohort with 13.9 bleeds per 1000 subjects is shown. For each decision threshold and its 
associated cost-benefit ratio, the net benefit of the CRUSADE, recalibrated CRUSADE and SWEDEHEART scores are shown. In addition, the 
net benefit assuming that all patients have a bleeding risk higher than the threshold is shown (All risk high). The net benefit assuming that all 
patients have a bleeding risk lower than the threshold is, by definition, zero. For example, at the threshold of 2% in a population with 13.9 bleeds 
(per 1000 subjects), the net benefit of using the CRUSADE, recalibrated CRUSADE and SWEDEHEART scores are –6.2, 2.8 and 5.1 bleeds 
respectively. The CRUSADE score is associated with negative net benefit for thresholds of 2-10%, indicating that its use is clinically harmful. 
Both the recalibrated CRUSADE score and the SWEDEHEART score show a positive net benefit and are considered clinically useful. Compared 
to the CRUSADE and recalibrated CRUSADE scores, the advantage of using the SWEDEHEART score at the 2% threshold is identification of 
11.3 and 2.3 additional bleedings, respectively, without increasing the number of false positive classifications. The SWEDEHEART score shows 
a higher net benefit across all decision thresholds in the range from 1 to 10%. 
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Table S5. C-index for SWEDEHEART score w/o CRP. 
C-index
N Bleeds ACTION CRUSADE 
Approximate 
SWEDEHEART 
Approximate 
SWEDEHEART w/o CRP 
Full 
SWEDEHEART 
Overall 97597 1356 0.73 (0.72-0.74) 0.72 (0.71-0.74) 0.80 (0.79-0.81) [0.80] 0.79 (0.77-0.80) [0.78] 0.81 (0.80-0.82) [0.80] 
Sex Female 34400 621 0.68 (0.66-0.70) 0.66 (0.64-0.68) 0.74 (0.72-0.76) [0.74] 0.72 (0.70-0.75) [0.72] 0.75 (0.73-0.77) [0.74] 
Male 63197 735 0.76 (0.74-0.78) 0.76 (0.74-0.77) 0.83 (0.81-0.84) [0.82] 0.81 (0.79-0.83) [0.81] 0.83 (0.82-0.85) [0.83] 
Missing 0 
Age < 75 56002 572 0.77 (0.75-0.79) 0.76 (0.74-0.78) 0.81 (0.80-0.83) [0.81] 0.79 (0.77-0.82) [0.79] 0.83 (0.81-0.84) [0.82] 
≥ 75 41594 784 0.67 (0.65-0.69) 0.66 (0.64-0.67) 0.76 (0.75-0.78) [0.76] 0.75 (0.74-0.77) [0.75] 0.77 (0.75-0.79) [0.76] 
Missing 1 
Anticoagulation No 91204 1228 0.73 (0.72-0.75) 0.72 (0.71-0.74) 0.80 (0.79-0.81) [0.80] 0.79 (0.77-0.80) [0.78] 0.81 (0.80-0.82) [0.80] 
Yes 5525 108 0.71 (0.67-0.76) 0.70 (0.65-0.74) 0.77 (0.73-0.82) [0.77] 0.78 (0.73-0.82) [0.78] 0.78 (0.73-0.82) [0.77] 
Missing 868 
Angiography No 22541 584 0.63 (0.61-0.65) 0.59 (0.57-0.62) 0.76 (0.74-0.79) [0.76] 0.76 (0.74-0.78) [0.76] 0.77 (0.75 0.79) [0.76] 
Yes 75056 772 0.75 (0.73-0.77) 0.74 (0.73-0.76) 0.79 (0.78-0.81) [0.79] 0.77 (0.76-0.79) [0.77] 0.80 (0.79-0.82) [0.79] 
Missing 0 
STEMI No 64730 896 0.74 (0.73-0.76) 0.72 (0.71-0.74) 0.82 (0.80-0.83) [0.81] 0.81 (0.79-0.82) [0.80] 0.82 (0.81-0.84) [0.82] 
Yes 31304 447 0.74 (0.72-0.76) 0.73 (0.71-0.75) 0.77 (0.75-0.79) [0.77] 0.75 (0.73-0.78) [0.75] 0.77 (0.75-0.80) [0.76] 
Missing 1563 
GFR < 60 28236 715 0.66 (0.65-0.68) 0.65 (0.63-0.67) 0.75 (0.73-0.77) [0.75] 0.74 (0.72-0.76) [0.74] 0.76 (0.74-0.78) [0.75] 
≥ 60 63999 578 0.73 (0.71-0.75) 0.71 (0.69-0.73) 0.79 (0.77-0.81) [0.78] 0.77 (0.75-0.79) [0.76] 0.80 (0.78-0.82) [0.79] 
Missing 5362 
CRP: C-reactive protein, GFR: glomerular filtration rate, STEMI: ST elevation myocardial infarction 
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Figure S1. The full model. 
CABG: coronary artery bypass grafting, CHF: chronic heart failure, CPR: cardiopulmonary resuscitation, CRP: 
C-reactive protein, HF: heart failure, PAD: peripheral artery disease, PCI percutaneous coronary intervention
Importance of each predictor in the full model, including contributions  from all higher-order 
effects, as measured by chance-corrected partial Wald χ². 
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Figure S2. SWEDEHEART Score Equation. 
The estimated in-hospital major bleeding probability is computed as 1 / [1 + exp(–bX)] where 
bX = 
–2.314
– 0.08253 t_Hemoglobin + 0.00002339 max(t_Hemoglobin – 106, 0)3
– 0.0001209 max(t_Hemoglobin – 127, 0)3 + 0.0003052 max(t_Hemoglobin – 138, 0)3
– 0.0003074 max(t_Hemoglobin – 148, 0)3 + 0.00009969 max(t_Hemoglobin – 163, 0)3
+ Female[–1.888 + 0.01696 t_Hemoglobin + 0.000009019 max(t_Hemoglobin – 106, 0)3
– 0.00003611 max(t_Hemoglobin – 127, 0)3 + 0.000005071 max(t_Hemoglobin – 138, 0)3
+ 0.00004395 max(t_Hemoglobin – 148, 0)3 – 0.00002192 max(t_Hemoglobin – 163, 0)3]
+ 0.04327 t_Age – 0.00004362 max(t_Age – 54, 0)3
+ 0.00009596 max(t_Age – 72, 0)3 – 0.00005234 max(t_Age – 87, 0)3
+ 0.106 t_CRP + 0.000009793 max(t_CRP – 0.47, 0)3 + 0.01781 max(t_CRP – 1.609, 0)3
– 0.02464 max(t_CRP – 2.48, 0)3 + 0.00682 max(t_CRP – 4.758, 0)3
+ 1.13 t_Creatinine – 1.232 max(t_Creatinine – 4.094, 0)3
+ 2.075 max(t_Creatinine – 4.443, 0)3 – 0.8433 max(t_Creatinine – 4.951, 0)3
uses the transformations 
t_Hemoglobin = min[max(Hemoglobin, 90), 170] 
t_Age = min[max(Age, 40), 95] 
t_CRP = ln[min(CRP, 235) + 1] 
t_Creatinine = ln{min[max(Creatinine, 40), 345] + 1} 
and min, max and ln denote the minimum, maximum and natural logarithm respectively. 
Example 1:Male with Hemoglobin = 135, Age = 85, CRP = 10 and Creatinine = 130. 
bX = 
–2.314
– 0.08253 * 135 + 0.00002339 * (135 – 106)3 – 0.0001209 * (135 – 127)3
+ 0.04327 * 85 – 0.00004362 * (85 – 54)3 + 0.00009596 * (85 – 72)3
+ 0.106 * 2.398 + 0.000009793 * (2.398 – 0.47)3 + 0.01781 * (2.398 – 1.609)3
+ 1.13 * 4.875 – 1.232 * (4.875 – 4.094)3 + 2.075 * (4.875 – 4.443)3 = –5.006
Probability(In-hospital major bleeding) = 1 / [1 + exp(5.222)] = 0.0067 
Example 2:Female with Hemoglobin = 135, Age = 85, CRP = 10 and Creatinine = 130. 
bX = 
–2.314
– 0.08253 * 135 + 0.00002339 * (135 – 106)3 – 0.0001209 * (135 – 127)3
– 1.888 + 0.01696 * 135 + 0.000009019 * (135 – 106)3 – 0.00003611 * (135 – 127)3
+ 0.04327 * 85 – 0.00004362 * (85 – 54)3 + 0.00009596 * (85 – 72)3
+ 0.106 * 2.398 + 0.000009793 * (2.398 – 0.47)3 + 0.01781 * (2.398 – 1.609)3
+ 1.13 * 4.875 – 1.232 * (4.875 – 4.094)3 + 2.075 * (4.875 – 4.443)3 = –4.402
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Probability(In-hospital major bleeding) = 1 / [1 + exp(4.522)] = 0.0121 
Figure S3. Calibration in Subgroups. 
Calibration plots for the recalibrated ACTION and CRUSADE scores and the 
SWEDEHEART score in subgroups. Deviation from perfect calibration (Ideal) represents 
bias in the predicted probabilities. The figure illustrates the observed proportion bleeding in 
the derivation cohort (with 95% confidence intervals) versus the predicted probability of 
bleeding (Apparent) and its optimism-corrected estimate (Optimism-corrected). The apparent 
and optimism-corrected calibration curves are almost indistinguishable, indicating no 
overfitting. 
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Figure S4. Score Equation for SWEDEHEART w/o CRP.
 The estimated in-hospital major bleeding probability is computed as 1 / [1 + exp(–bX)] 
where bX = 
–1.612
– 0.08481 t_Hemoglobin + 0.00002114 max(t_Hemoglobin – 106, 0)3
– 0.0001064 max(t_Hemoglobin – 127, 0)3 + 0.0002863 max(t_Hemoglobin – 138, 0)3
– 0.0003021 max(t_Hemoglobin – 148, 0)3 + 0.0001011 max(t_Hemoglobin – 163, 0)3
+ Female[–1.611 + 0.0143 t_Hemoglobin + 0.00001217 max(t_Hemoglobin – 106, 0)3
– 0.00004872 max(t_Hemoglobin – 127, 0)3 + 0.00001856 max(t_Hemoglobin – 138, 0)3
+ 0.00003975 max(t_Hemoglobin – 148, 0)3 – 0.00002176 max(t_Hemoglobin – 163, 0)3]
+ 0.0439 t_Age – 0.00004332 max(t_Age – 54, 0)3
+ 0.0000953 max(t_Age – 72, 0)3 – 0.00005198 max(t_Age – 87, 0)3
+ 1.097 t_Creatinine – 1.006 max(t_Creatinine – 4.094, 0)3
+ 1.696 max(t_Creatinine – 4.443, 0)3 – 0.6891 max(t_Creatinine – 4.951, 0)3
uses the transformations 
t_Hemoglobin = min[max(Hemoglobin, 90), 170] 
t_Age = min[max(Age, 40), 95] 
t_CRP = ln[min(CRP, 235) + 1] 
t_Creatinine = ln{min[max(Creatinine, 40), 345] + 1} 
and min, max and ln denote the minimum, maximum and natural logarithm respectively. 
Example 1: Male with Hemoglobin = 135, Age = 85 and Creatinine = 130. 
bX = 
–1.612
– 0.08481 * 135 + 0.00002114 * (135 – 106)3 – 0.0001064 * (135 – 127)3
+ 0.0439 * 85 – 0.00004332 * (85 – 54)3 + 0.0000953 * (85 – 72)3
+ 1.097 * 4.875 – 1.006 * (4.875 – 4.094)3 + 1.696 * (4.875 – 4.443)3 = –4.945
Probability(In-hospital major bleeding) = 1 / [1 + exp(4.945)] = 0.0071 
Example 2: Female with Hemoglobin = 135, Age = 85 and Creatinine = 130. 
bX = 
–1.612
– 0.08481 * 135 + 0.00002114 * (135 – 106)3 – 0.0001064 * (135 – 127)3
– 1.611 + 0.0143 * 135 + 0.00001217 * (135 – 106)3 – 0.00004872 * (135 – 127)3
+ 0.0439 * 85 – 0.00004332 * (85 – 54)3 + 0.0000953 * (85 – 72)3
+ 1.097 * 4.875 – 1.006 * (4.875 – 4.094)3 + 1.696 * (4.875 – 4.443)3 = –4.353
Probability(In-hospital major bleeding) = 1 / [1 + exp(4.353)] = 0.0127 
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Figure S5. Nomogram for SWEDEHEART score w/o CRP. 
Nomogram for the SWEDEHEART score without CRP. To use the nomogram for an 
individual patient, the points for each predictor are read at the vertical line from the predictor 
value to the Points line (top). The total points are calculated and a vertical line from this value 
on the Total Points line to the Bleeding risk line (bottom) provides the estimated probability 
of in-hospital major bleeding risk. 
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Figure S6. Calibration for SWEDEHEART score w/o CRP. 
Calibration plots for the recalibrated CRUSADE score, the SWEDEHEART score and the 
SWEDEHEART score without CRP. Deviation from perfect calibration (Ideal) represents 
bias in the predicted probabilities. The figure illustrates the observed proportion bleeding in 
the derivation cohort (with 95% confidence intervals) versus the predicted probability of 
bleeding (Apparent) and its optimism-corrected estimate (Optimism-corrected). The apparent 
and optimism-corrected calibration curves are almost indistinguishable, indicating no 
overfitting. Dow
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